MarketPeel
Insider Trading Intelligence
LZ

Lota S. Zoth

INO
DIRECTOR · INOVIO PHARMACEUTICALS, INC. · CIK 0001278219
FILING MIX · LIFETIME67%/33%
BUYS
29
SELLS
14
TOTAL VALUE
$37.8K
COMPANIES
4
ACTIVE SINCE
Jan 2020
HOLDINGS NOW
92,342
AVG SELL PX
$2.85
TRADE KIND
SHOWING 43 / 43
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
5 backtested trades · 8 horizonsHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Lota S. Zoth, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d5+40.00%-1.22%+0.84%-2.06%+2.01%
14d5+60.00%-1.18%+1.07%-2.25%-4.27%
30d5+60.00%+3.03%+0.06%+2.97%-11.96%
60d5+60.00%-5.68%-0.26%-5.41%-4.07%
90d5+60.00%+5.50%+5.60%-0.10%-11.25%
180d5+60.00%-11.32%+4.33%-15.65%-20.16%
1y5+80.00%-40.68%+7.90%-48.58%-67.24%
2y5+100.00%-73.59%+18.24%-91.83%-88.26%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
INO · 34,200 shares · as of May 20, 2026
014,60429,20843,81258,416202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 29 buys / 14 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ENGN
ENGENE THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
31,00031,000Jun 16, 2026Jun 17, 2026View →
INO
INOVIO PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
41,80041,800May 20, 2026May 21, 2026View →
INO
INOVIO PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
34,20034,200May 20, 2026May 21, 2026View →
FFIN
FIRST FINANCIAL BANKSHARES INC
PURCHASEGRANT
Stock grant
2,1422,142Apr 28, 2026May 5, 2026View →
ENGN
ENGENE THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
22,50022,500Jun 16, 2025Jun 16, 2025View →
INO
INOVIO PHARMACEUTICALS, INC.
SALE
2,1670May 21, 2025May 21, 2025View →
INO
INOVIO PHARMACEUTICALS, INC.
PURCHASE
2,1678,726May 21, 2025May 21, 2025View →
ENGN
ENGENE THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
20,00020,000Jun 15, 2024Jun 18, 2024View →
INO
INOVIO PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
2,9172,917May 21, 2024May 22, 2024View →
INO
INOVIO PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
2,1672,167May 21, 2024May 22, 2024View →
INO
INOVIO PHARMACEUTICALS, INC.
PURCHASE
2,1666,559May 15, 2024May 16, 2024View →
INO
INOVIO PHARMACEUTICALS, INC.
SALE
2,1660May 15, 2024May 16, 2024View →
ENGN
ENGENE THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
40,00040,000Mar 21, 2024Mar 25, 2024View →
INO
INOVIO PHARMACEUTICALS, INC.
SALE
5,700$0.56$3.2K52,716Jun 5, 2023Jun 5, 2023View →
INO
INOVIO PHARMACEUTICALS, INC.
PURCHASE
19,00058,416May 16, 2023May 16, 2023View →
INO
INOVIO PHARMACEUTICALS, INC.
SALE
19,0000May 16, 2023May 16, 2023View →
INO
INOVIO PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
35,00035,000May 15, 2023May 16, 2023View →
INO
INOVIO PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
26,00026,000May 15, 2023May 16, 2023View →
ZYME
ZYMEWORKS INC.
PURCHASEGRANT
Stock grant
25,00025,000Dec 21, 2022Dec 23, 2022View →
INO
INOVIO PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
28,00028,000May 16, 2022May 17, 2022View →
INO
INOVIO PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
19,00019,000May 16, 2022May 17, 2022View →
INO
INOVIO PHARMACEUTICALS, INC.
SALE
3,600$1.98$7.1K39,416May 16, 2022May 17, 2022View →
INO
INOVIO PHARMACEUTICALS, INC.
PURCHASE
18,00043,016May 13, 2022May 17, 2022View →
INO
INOVIO PHARMACEUTICALS, INC.
SALE
18,0000May 13, 2022May 17, 2022View →
INO
INOVIO PHARMACEUTICALS, INC.
SALE
961$5.01$4.8K25,016Jan 5, 2022Jan 5, 2022View →
INO
INOVIO PHARMACEUTICALS, INC.
SALE
4,0900Jan 3, 2022Jan 5, 2022View →
INO
INOVIO PHARMACEUTICALS, INC.
PURCHASE
4,09025,977Jan 3, 2022Jan 5, 2022View →
INO
INOVIO PHARMACEUTICALS, INC.
SALE
2,045$6.62$13.5K21,887May 17, 2021May 17, 2021View →
INO
INOVIO PHARMACEUTICALS, INC.
SALE
8,7000May 14, 2021May 17, 2021View →
INO
INOVIO PHARMACEUTICALS, INC.
PURCHASE
8,70023,932May 14, 2021May 17, 2021View →
INO
INOVIO PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
27,00027,000May 13, 2021May 17, 2021View →
INO
INOVIO PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
18,00018,000May 13, 2021May 17, 2021View →
ZYME
ZYMEWORKS INC.
PURCHASEGRANT
Stock grant
9,0009,000May 6, 2021May 7, 2021View →
INO
INOVIO PHARMACEUTICALS, INC.
SALE
961$9.48$9.1K15,232Jan 5, 2021Jan 5, 2021View →
INO
INOVIO PHARMACEUTICALS, INC.
SALE
4,0904,090Jan 3, 2021Jan 5, 2021View →
INO
INOVIO PHARMACEUTICALS, INC.
PURCHASE
4,09016,193Jan 3, 2021Jan 5, 2021View →
INO
INOVIO PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
8,7008,700May 14, 2020May 15, 2020View →
INO
INOVIO PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
13,30013,300May 14, 2020May 15, 2020View →
ZYME
ZYMEWORKS INC.
PURCHASEGRANT
Stock grant
9,0009,000May 8, 2020May 11, 2020View →
INO
INOVIO PHARMACEUTICALS, INC.
PURCHASE
8,01312,103May 8, 2020May 8, 2020View →
INO
INOVIO PHARMACEUTICALS, INC.
SALE
8,0130May 8, 2020May 8, 2020View →
INO
INOVIO PHARMACEUTICALS, INC.
PURCHASE
4,0904,090Jan 3, 2020Jan 6, 2020View →
INO
INOVIO PHARMACEUTICALS, INC.
SALE
4,0908,180Jan 3, 2020Jan 6, 2020View →
Other insiders · INO
Loading peer insiders…
About this filer
CIK 0001278219
ROLE
Director
PRIMARY
INO
COMPANIES
4
ACTIVE SINCE
Jan 2020
MARKETPEEL · /INSIDER/0001278219DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback